TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort

Coates, 2007, Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98, J. Clin. Oncol., 25, 486, 10.1200/JCO.2006.08.8617 Howell, 2005, Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5years' adjuvant treatment for breast cancer, Lancet, 365, 60, 10.1016/S0140-6736(04)17666-6 Coombes, 2007, Survival and safety of exemestane versus tamoxifen after 2–3years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial, Lancet, 369, 559, 10.1016/S0140-6736(07)60200-1 Servitja, 2015, Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance, Ther. Adv. Med. Oncol., 7, 291, 10.1177/1758834015598536 Henry, 2012, Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer, J. Clin. Oncol., 30, 936, 10.1200/JCO.2011.38.0261 Hadji, 2014, COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy, Ann. Oncol., 25, 372, 10.1093/annonc/mdt513 Geisler, 2002, Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study, J. Clin. Oncol., 20, 751, 10.1200/JCO.2002.20.3.751 Geisler, 1998, In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients, Clin. Cancer Res., 4, 2089 Hadji, 2009, Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis, Crit. Rev. Oncol. Hematol., 69, 73, 10.1016/j.critrevonc.2008.07.013 Amir, 2011, Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis, J. Natl. Cancer Inst., 103, 1299, 10.1093/jnci/djr242 1994, Assessment of fracture risk and its application to screening for postmenopausal osteoporosis, 843, 1 Bouxsein, 2005, Determinants of skeletal fragility, Best Pract. Res. Clin. Rheumatol., 19, 897, 10.1016/j.berh.2005.07.004 Brandi, 2009, Microarchitecture, the key to bone quality, Rheumatology (Oxford), 48 Rice, 1988, On the dependence of the elasticity and strength of cancellous bone on apparent density, J. Biomech., 21, 155, 10.1016/0021-9290(88)90008-5 Ammann, 2003, Bone strength and its determinants, Osteoporos. Int., 14 Pothuaud, 2008, Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture, Bone, 42, 775, 10.1016/j.bone.2007.11.018 Winzenrieth, 2013, Three-dimensional (3D) microarchitecture correlations with 2D projection image gray-level variations assessed by trabecular bone score using high-resolution computed tomographic acquisitions: effects of resolution and noise, J. Clin. Densitom., 16, 287, 10.1016/j.jocd.2012.05.001 Hans, 2011, Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae, J. Clin. Densitom., 14, 302, 10.1016/j.jocd.2011.05.005 Boutroy, 2013, Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study, Osteoporos. Int., 24, 77, 10.1007/s00198-012-2188-2 Rabier, 2010, A multicentre, retrospective case-control study assessing the role of trabecular bone score (TBS) in menopausal Caucasian women with low areal bone mineral density (BMDa): analysing the odds of vertebral fracture, Bone, 46, 176, 10.1016/j.bone.2009.06.032 Del Rio, 2013, Is bone microarchitecture status of the lumbar spine assessed by TBS related to femoral neck fracture? A Spanish case-control study, Osteoporos. Int., 24, 991, 10.1007/s00198-012-2008-8 Pedrazzoni, 2014, Longitudinal changes of trabecular bone score after estrogen deprivation: effect of menopause and aromatase inhibition, J. Endocrinol. Investig., 37, 871, 10.1007/s40618-014-0125-2 Kalder, 2014, Effects of exemestane and tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer, J. Clin. Densitom., 17, 66, 10.1016/j.jocd.2013.03.003 Kalder, 2015, Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy, Osteoporos. Int., 26, 353, 10.1007/s00198-014-2955-3 Reginster, 2000, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group, Osteoporos. Int., 11, 83, 10.1007/s001980050010 Brufsky, 2009, Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results, Clin. Breast Cancer, 9, 77, 10.3816/CBC.2009.n.015 Eidtmann, 2010, Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study, Ann. Oncol., 21, 2188, 10.1093/annonc/mdq217 Van Poznak, 2010, Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial, J. Clin. Oncol., 28, 967, 10.1200/JCO.2009.24.5902 Valachis, 2010, Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis, Gynecol. Oncol., 117, 139, 10.1016/j.ygyno.2009.12.001 Coleman, 2015, Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials, Lancet, 386, 1353, 10.1016/S0140-6736(15)60908-4 Krieg, 2013, Effects of anti-resorptive agents on trabecular bone score (TBS) in older women, Osteoporos. Int., 24, 1073, 10.1007/s00198-012-2155-y Popp, 2013, Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study, J. Bone Miner. Res., 28, 449, 10.1002/jbmr.1775 Winer, 2005, American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer: status report 2004, J. Clin. Oncol., 23, 619, 10.1200/JCO.2005.09.121 Cormier, 2012 Sawada, 2007, Peripheral quantitative computed tomography (pQCT) is useful for monitoring bone mineral density of the patients who receive hormone replacement therapy, Maturitas, 56, 343, 10.1016/j.maturitas.2006.08.006 Cranney, 2007, Low bone mineral density and fracture burden in postmenopausal women, CMAJ, 177, 575, 10.1503/cmaj.070234 Siris, 2004, Bone mineral density thresholds for pharmacological intervention to prevent fractures, Arch. Intern. Med., 164, 1108, 10.1001/archinte.164.10.1108 Siris, 2001, Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment, JAMA, 286, 2815, 10.1001/jama.286.22.2815 Hordon, 2000, Trabecular architecture in women and men of similar bone mass with and without vertebral fracture: I. two-dimensional histology, Bone, 27, 271, 10.1016/S8756-3282(00)00329-X Boutroy, 2005, In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography, J. Clin. Endocrinol. Metab., 90, 6508, 10.1210/jc.2005-1258 Genant, 2008, Advanced CT bone imaging in osteoporosis, Rheumatology, 47, 10.1093/rheumatology/ken180 Krug, 2008, In vivo ultra-high-field magnetic resonance imaging of trabecular bone microarchitecture at 7T, J. Magn. Reson. Imaging, 27, 854, 10.1002/jmri.21325 Harvey, 2015, Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice, Bone, 78, 216, 10.1016/j.bone.2015.05.016 Roux, 2013, The predictive value of trabecular bone score (TBS) on whole lumbar vertebrae mechanics: an ex vivo study, Osteoporos. Int., 24, 2455, 10.1007/s00198-013-2316-7 Pothuaud, 2009, Evaluation of the potential use of trabecular bone score to complement bone mineral density in the diagnosis of osteoporosis: a preliminary spine BMD–matched, Case-Control Study, J. Clin. Densitom., 12, 170, 10.1016/j.jocd.2008.11.006 Dufour, 2013, Generation and validation of a normative, age-specific reference curve for lumbar spine trabecular bone score (TBS) in French women, Osteoporos. Int., 24, 2837, 10.1007/s00198-013-2384-8 Simonelli, 2014, Creation of an age-adjusted, dual-energy x-ray absorptiometry-derived trabecular bone score curve for the lumbar spine in non-Hispanic US White women, J. Clin. Densitom., 17, 314, 10.1016/j.jocd.2013.09.002 Prasad, 2016, Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors, Osteoporosis Eastell, 2008, Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230, J. Clin. Oncol., 26, 1051, 10.1200/JCO.2007.11.0726 Coleman, 2010, Reversal of skeletal effects of endocrine treatments in the intergroup exemestane study, Breast Cancer Res. Treat., 124, 153, 10.1007/s10549-010-1121-7 Perez, 2006, Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17, J. Clin. Oncol., 24, 3629, 10.1200/JCO.2005.05.4882 Prieto-Alhambra, 2012, Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study, Breast Cancer Res. Treat., 133, 1159, 10.1007/s10549-012-2013-9 Rodriguez-Sanz, 2015, CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss, J. Mol. Endocrinol., 55, 69, 10.1530/JME-15-0079 Ross, 2011, The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know, J. Clin. Endocrinol. Metab., 96, 53, 10.1210/jc.2010-2704 Rodriguez-Sanz, 2016, AI-related BMD variation in actual practice conditions: a prospective cohort study, Endocr. Relat. Cancer, 24, 16 Resch, 1998, Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer, Acta Oncol., 37, 661, 10.1080/028418698430007 McCaig, 2010, A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer, Breast Cancer Res. Treat., 119, 643, 10.1007/s10549-009-0646-0 McCaig, 2009, A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer, Breast Cancer Res. Treat., 119, 643, 10.1007/s10549-009-0646-0 Brufsky, 2012, Final 5-year results of Z-FAST trial, Cancer, 118, 1192, 10.1002/cncr.26313 Coleman, 2013, Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results, Ann. Oncol., 24, 398, 10.1093/annonc/mds277 van Londen, 2010, The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial, Bone, 46, 655, 10.1016/j.bone.2009.10.019 Luck, 2008, The influence of basal phenotype on the metastatic pattern of breast cancer, Clin. Oncol. (R. Coll. Radiol.), 20, 40, 10.1016/j.clon.2007.10.002